Dynogen Pharmaceuticals, Inc. Announces Positive Results in Phase 2 IBS-d Study
Published: Dec 17, 2007
WALTHAM, Mass.--(BUSINESS WIRE)--Dynogen Pharmaceuticals, Inc. today announced positive results from its Phase 2 trial of DDP225 in patients with irritable bowel syndrome with diarrhea (IBS-d). The randomized, double-blind, placebo controlled trial generated statistically significant results for the clinical endpoint of relief from abdominal pain or discomfort associated with IBS-d. Detailed results will be submitted for disclosure in a peer-reviewed journal or at a future medical conference.